FDA Approves Ryoncil Cell Therapy for Graft-versus-Host Disease (GVHD)
The U.S. Food and Drug Administration (FDA) has approved Mesoblast’s cell therapy, Ryoncil, for the treatment of a condition known as graft-versus-host disease (GVHD), which occurs after stem cell or bone marrow transplantation.
Ryoncil is the first mesenchymal stem cell therapy approved for pediatric patients aged two months and older whose GVHD symptoms have not responded to standard steroid treatments.
GVHD is an inflammatory reaction caused by the immune system, occurring when transplanted stem cells attack the recipient’s body cells. This condition can jeopardize the success of a bone marrow transplant.
The FDA advises physicians treating this condition to closely monitor the infusion of Ryoncil. If symptoms such as shortness of breath, low blood pressure, fever, or rapid breathing occur, the infusion should be discontinued.
End of Message
Feel free to share this content with attribution to The World of Health and Medicine.
